On November 3, 2026, Vicore Pharma Holding AB announced the formation of its nomination committee for the 2027 Annual General Meeting (AGM), scheduled for May 5, 2027. This update is crucial as it lays the groundwork for the company’s governance and strategic decisions moving forward.

Vicore Pharma Holding AB is a biopharmaceutical company focused on unlocking the potential of angiotensin II type 2 receptor agonists. The company operates under the Standard Industrial Classification (SIC) of 2834, which pertains to Pharmaceutical Preparations. Vicore is publicly traded on Nasdaq under the ticker symbols VICO in Sweden and VCRE in the U.S.

The filing details that the nomination committee will consist of members appointed by the three largest shareholders as of August 31, 2026. These members include Staffan Lindstrand from HealthCap VII L.P., Jan Särlvik from the Fourth Swedish National Pension Fund, and Ivo Staijen from HBM Healthcare Investments (Cayman) Ltd. Vicore’s chairman, Hans Schikan, will also serve on the committee as its convener.

The main responsibilities of the nomination committee include preparing proposals for the number of board members, electing a chairman, determining board fees, and setting rules for the appointment of the nomination committee for the 2028 AGM.

The establishment of this committee may impact various stakeholders, including shareholders and potential investors, as it reflects Vicore's commitment to governance and transparency. Shareholders are encouraged to submit their comments or proposals to the committee by January 15, 2027, further emphasizing the company’s dedication to engaging with its investor base.

The AGM will be a significant event for Vicore as it will address crucial governance issues that could shape the company’s future. The nomination committee’s proposals will be presented in the notice convening the AGM and will also be available on the company’s website.

For further information, shareholders and interested parties can contact Hans Jeppsson, CFO, at the provided contact details in the press release.